Nurtec ODT (rimegepant) vs Ubrelvy (ubrogepant)

Nurtec ODT (rimegepant) vs Ubrelvy (ubrogepant)

Nurtec ODT (rimegepant) and Ubrelvy (ubrogepant) are both oral calcitonin gene-related peptide (CGRP) receptor antagonists used for the acute treatment of migraine with or without aura in adults. Nurtec ODT is unique in that it is available as an orally disintegrating tablet, potentially offering convenience for those who have difficulty swallowing pills, and it has the additional indication for the preventive treatment of episodic migraine. In contrast, Ubrelvy is a traditional oral tablet and is solely indicated for the acute treatment of migraine, with no preventive indication, which may be a consideration for patients seeking a medication for immediate relief only.

Difference between Nurtec ODT and Ubrelvy

Metric Nurtec ODT (rimegepant) Ubrelvy (ubrogepant)
Generic name Rimegepant Ubrogepant
Indications Acute treatment of migraine with or without aura in adults Acute treatment of migraine with or without aura in adults
Mechanism of action Calcitonin gene-related peptide (CGRP) receptor antagonist Calcitonin gene-related peptide (CGRP) receptor antagonist
Brand names Nurtec ODT Ubrelvy
Administrative route Oral disintegrating tablet Oral tablet
Side effects Nausea, dizziness, fatigue, dry mouth, abdominal pain Nausea, somnolence, dry mouth, fatigue, dizziness
Contraindications Hypersensitivity to rimegepant, concomitant administration with strong CYP3A4 inhibitors Hypersensitivity to ubrogepant, concomitant administration with strong CYP3A4 inhibitors
Drug class CGRP receptor antagonist CGRP receptor antagonist
Manufacturer Biohaven Pharmaceuticals Allergan plc

Efficacy

Nurtec ODT (Rimegepant) for Migraine

Nurtec ODT (rimegepant) is an orally disintegrating tablet designed for the acute treatment of migraine with or without aura in adults. The efficacy of Nurtec ODT for the treatment of migraine was established in a multicenter, randomized, double-blind, placebo-controlled trial. In this trial, a significant percentage of patients treated with Nurtec ODT experienced pain freedom at two hours compared to those who received a placebo. Additionally, many patients reported relief from the most bothersome migraine symptom within the same time frame. The benefits of Nurtec ODT include its rapid onset of action and the convenience of its orally disintegrating formulation, which does not require water to take.

Ubrelvy (Ubrogepant) for Migraine

Ubrelvy (ubrogepant) is an oral medication indicated for the acute treatment of migraine with or without aura in adults. The efficacy of Ubrelvy was demonstrated in two randomized, double-blind, placebo-controlled trials. These studies showed that a significant proportion of patients achieved pain relief at two hours after taking a single dose of Ubrelvy compared to placebo. Furthermore, a notable number of patients also attained freedom from their most bothersome migraine symptom, whether it was nausea, light sensitivity, or sound sensitivity, within two hours of taking the medication.

Comparison of Efficacy

Both Nurtec ODT and Ubrelvy belong to a class of drugs called CGRP receptor antagonists and share a similar mechanism of action in treating migraines. When comparing the efficacy of Nurtec ODT and Ubrelvy, clinical trials indicate that both medications are effective in providing relief from migraine pain and associated symptoms within two hours for a significant number of patients. The choice between these medications may be influenced by patient preference, ease of administration, speed of relief, cost, and insurance coverage.

Considerations for Use

When considering the use of Nurtec ODT or Ubrelvy, it is important for patients to discuss their medical history and potential drug interactions with their healthcare provider. Both medications are generally well-tolerated, but as with any medication, they can have side effects. The decision to use either Nurtec ODT or Ubrelvy should be made in consultation with a healthcare provider, taking into account the individual patient's needs and the medication's efficacy profile. It is also important to note that while both medications are approved for the acute treatment of migraine, they are not intended for the prevention of migraine.

Regulatory Agency Approvals

Nurtec ODT
  • Food and Drug Administration (FDA), USA
Ubrelvy
  • Food and Drug Administration (FDA), USA

Access Nurtec ODT or Ubrelvy today

If Nurtec ODT or Ubrelvy are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email:

Contact us
US United States 1